Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study

OBJECTIVETo determine the effect of erenumab, a human monoclonal antibody targeting the calcitonin gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine (CM). METHODSIn this double-blind, placebo-controlled study,...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neurology 2019-05, Vol.92 (19), p.e2250-e2260
Hauptverfasser:	Lipton, Richard B, Tepper, Stewart J, Reuter, Uwe, Silberstein, Stephen, Stewart, Walter F, Nilsen, Jon, Leonardi, Dean K, Desai, Pooja, Cheng, Sunfa, Mikol, Daniel D, Lenz, Robert
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - therapeutic use Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use Double-Blind Method Female Humans Male Middle Aged Migraine Disorders - drug therapy Patient Reported Outcome Measures Quality of Life Surveys and Questionnaires Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!